Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-Myeloablative Allo-SCT with Daclizumab for Hematologic Malignancies
NCT00006350Phase 2Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Jan 2000
- Primary completion
- Nov 2001
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daclizumab in hematologic malignancy, sponsored by University of Maryland, Baltimore. Started Jan 2000; status: completed.
02
Drugs
daclizumab
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT00006350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006350.